Scienture Holdings, Inc. · NASDAQ:SCNX
Scienture — Investor Presentation (November 2025)
22 slides from Scienture's investor presentation, Nov 18, 2025
Slide 1: Scienture Holdings
$3} Scienture Holdings We invest in creating better health outcomes NASDAQ: SCNX
Slide 2: Safe Harbor Statement and Non-GAAP Measures
Safe Harbor Statement and Non-GAAP Measures th herein contains forward-I tatements within the federal securities laws, including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Forward-looking statements include all statements that donot cate any to historia or cr
Slide 3: Scienture Holdings, Inc | About Us
Scienture Holdings, Inc | About Us Scienture Holdings is a fully integrated pharmaceutical product group committed to providing greater value to patients, physicians, and caregivers through the development, commercialization, and distribution of innovative specialty products designed to meet unmet c
Slide 4: Leadership
Leadership Executive Management Shankar Hariharan, Ph.D. Executive Chairman & CEO, Director Over 35 years of experience in Pharmaceutical Industry. Involved with development and commercialization of Celexa® (>$2B), Lexapro® ($4B), Namenda® (>$2B), Megace ES® (>$100M). He has founded and has held boa
Slide 5: Our Mission
Our Mission Our mission is to bring patients selectively designed drug product innovations by channeling the power of R&D through accelerated, nuanced commercialization Beginnings Our founders identified critical gaps in care—challenging treatment paradigms, safety and efficacy limitations, access,
Slide 6: Prioritizing Patients. Improving Outcomes.
Prioritizing Patients. 33} Scienture Improving Outcomes. (a wholly owned subsidiary of Scienture Holdings, Inc.)
Slide 7: Delivering Better™ | Improving today's medicines for a better tomorrow
Delivering Better™ | Improving today’s medicines for a better tomorrow We fuse our core capabilities to these cornerstones, delivering scientific and commercial solutions, addressing gaps in therapy treatment, and leading to better health outcomes. Deliver Scienture Chemistry Data-Driven Insights Fr
Slide 8: Product Portfolio
Product Portfolio Anticipated Early Human Studies NDA/ BLA Anticipated Product | Indication Development Animal Studies Phase 1 Phase 2 Phase 3 Timeline Launch Sree: oe, oe ire) erenon tr gevlaria ond pearl one g ia (Approved) (Launched) ld ) i esa Eo Seen g Not Required (approved) 01-2026 SCN-106**
Slide 9: Intellectual Property | USPTO Granted Patents and Pending Applications
Intellectual Property | USPTO Granted Patents and Pending Applications * Arbli™ (SCN-102) + Patent #: 11,890,273, Issue Date: February 6, 2024, titled “LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE”, Expiration Date: October 7, 2041 + Patent # 12,156,869; Issue Date: December 3, 2024, titled “LOSA
Slide 10: Arbli™ (losartan potassium) Oral Suspension
Arbli™ (losartan potassium) Oral Suspension 10 mg / mL 165 mL bottle The first and only FDA approved liquid losartan formulation available in the US Market First and only liquid ARB | FDA Approved March 13, 2025 Arbli™ (losartan potassium) Oral Suspension ri Uf Ready-to-dispense flexible dosing form
Slide 11: Commercial Product Acquisition - Commercial Launch in Q2 6
Commercial Product Acquisition - Commercial Launch in Q2 2026 SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P. Scienture entered into a definitive agreement with SUMMIT BIOSCIENCES INC. (a wholly own
Slide 12: Commercial Operations | Strategy & Execution
Commercial Operations | Strategy & Execution We have developed a sound strategy and designed a robust Field Sales F2F + Virtual Promotion coordinated commercial execution plan A + €80 Partner + Top Decile and Regional Tiering + Targeting & Segmentation Promotional + Branding Omnichannel + CRM + Pati
Slide 13: Commercial Operations | Contracting for Access
Commercial Operations | Contracting for Access Our integrated solutions rely on our contracted partners and their services to ensure patient friction is minimized and mitigated Payers + Contracted Entities + Zinc |CVS/Caremark/Aetna @CVS caremark’ XQ oprumax 24 EXPRESS SCRIPTS” + Emisar |UnitedHealt
Slide 14: Arbli™ Go to Market Progress
Arbli™ (losartan potassium) Oral Suspension 10 mg / mL 165 mL bottle Go to Market Progress — IQVIA (MAT September 2025) Losartan market size of $256M in annual sales and 71M prescriptions Field Sales F2F + Promotional + Branding Virtual Promotion fi Design Ag . eyes tale ies Acute and Specialty = Re
Slide 15: SCN-104 | Fixed Dose Injection Pen
SCN-104 | Fixed Dose Injection Pen Product Description Easy-to-use, multidose pen based delivery system for self injection and increased convenience. Value Proposition & Easy-to-use, multi-dose pen injector Therapeutic Area NS (Migraine) Indicated for acute treatment of migraine headaches with or wi
Slide 16: SCN-106 | Biosimilar Product
SCN-106 | Biosimilar Product Product Description Therapeutic Area US Market {21 IP Strategy Large Molecule Biosimilar CVS (hospital based) Total Market Size (IQVIA + Potential process/formulation IP coverage for CV use September 2025)—$670MM. Value Proposition Regulatory Path and Clinical Strategy +
Slide 17: SCN-107 | Extended-Release Injection
SCN-107 | Extended-Release Injection Product Description Microsphere based long-acting injection with immediate release component Value Proposition on Potential reduction to opioid usage following surgeries A complicated formulation with highly involved manufacturing. ‘Sour: HA NEP MAT Sp 202, Dt on
Slide 18: Financial Model and Outlook
Financial Model and Outlook 8 9 0 0 Net Sales $ 8.1 $ 26.7 $ 59.1 $ 131.3 $ 225.0 $ 270.3 Gross Margin $ 7.1 =$ 22.9 $ 51.4 $ 109.8 $ 188.9 $ 229.1 Gross Margin % 88% 86% 87% 84% 84% 85% SG&A $ (106) $ (13.0) $ (16.2) $ (17.4) $ (19.0) $ (21.0) Operating Profit $ (3.5) $ 9.9 $ 35.2. $ 92.4 $ 169.9 $
Slide 19: Appendix
Appendix
Slide 20: Consolidated Balance Sheet
Consolidated Balance Sheet Cash* Notes receivable - related party Current assets Goodwill and intangibles Investments Total assets Accounts payable and accrued liabilities** Warrant liability Convertible notes*** Development agreement liability**** Stockholders' equity Total liabilities and stockhol
Slide 21: Income Statement
Income Statement Summary pro forma consolidated income sheet data for YTD September 30,2025 Revenues 600,308 Gross profit 575,294 Research and development 1,587,572 General and administrative 6,449,110 Wage and Salary Expense 1,721,554 Other operating expenses 2,945,089 Non-operating income (expense
Slide 22: Thank you!
Thank you! SCIENTURE HOLDINGS, INC. 20 Austin Blvd Commack, NY 11725 Phone: (866) 468-6535 Email: IR@Scienture.com Scienture Holdings scienture.com
Scienture Holdings — Investor Presentation (November 2025) on 6ix